---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-042635"
form_type: "8-K"
ticker: "IBO"
cik: "0001834105"
company_name: "IMPACT BIOMEDICAL INC."
filed_at: "2026-09-14T23:43:54+00:00"
generated_at: "2026-09-15T10:05:21.777849+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Impact Biomedical corrects merger ratio to 1:1, sets 1-for-12.62 reverse split effective Sept 23

## Summary
- Reverse stock split 1-for-12.62 effective Sept 23, 2026; shares drop from ~107.8M to ~8.5M.
- Corrected merger ratio: 1 Zoar share per 1 Impact share after split, replacing incorrect 1-for-4 in Sept 11 release.
- Stockholders authorized split Dec 30, 2025 within 1-for-12.48 to 1-for-50 range; CEO fixed ratio at 12.62.
- Split aims to support Zoar merger and regain NYSE American continued-listing compliance; no assurance of success.
- Transfer agent Equiniti manages exchange; fractional shares rounded up; new CUSIP for IBO.

## SEC filing metadata
- accession: 0001493152-26-042635
- form_type: 8-K
- ticker: IBO
- cik: 0001834105
- company_name: IMPACT BIOMEDICAL INC.
- filed_at: 2026-09-14T23:43:54+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1834105/000149315226042635/0001493152-26-042635-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1834105/000149315226042635/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-042635
- JSON: https://secwatch.observer/filing/0001493152-26-042635.json
- Plain text: https://secwatch.observer/filing/0001493152-26-042635.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.